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Here we present original data related to the research paper enti-
tled “Proteome analysis in dystrophic mdx mouse muscle reveals a
drastic alteration of Key Metabolic and Contractile Proteins after
chronic exercise and the potential modulation by anti-oxidant
compounds” (Gamberi et al., 2018) [1]. The dystrophin-deficient
mdx mouse is the most common animal model for Duchenne
muscular dystrophy. The mdx mice phenotype of the disorder is
milder than in human sufferers and it can be worsened by chronic
treadmill exercise. Apocynin and taurine are two antioxidant
compounds proved to be beneficial on some pathology related
parameters (Schröder and Schoser, 2009) [2]. This article reports
the detailed proteomic data on protein abundance alterations, in
tibialis anterior muscle of mdx mice, induced by chronic exercise
protocol. A selected group of mdx mice was also treated with
apocynin and taurine during this protocol. Detailed MS data,
comparison between mdx vs wild type, exercised mdx vs wildvier Inc. This is an open access article under the CC BY license
.jprot.2017.09.009









T. Gamberi et al. / Data in Brief 18 (2018) 555–575556type, and complete analysis of spot variation are provided. Fur-
thermore, in wild type mice subjected to the same exercise pro-
tocol, the abundance of key proteins, resulted modified in exer-
cised mdx, were analyzed by western blot.
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications TableSubject area Biologyore specific subject area Mdx mice model for Duchenne muscular dystrophy.
ype of data Table, text file, graph
ow data was acquired 2DE gels were analyzed with Progenesis SameSpots software v4.0
(Nonlinear Dynamics, UK). MS and MSMS data were obtained with
Ultraflex III MALDI- TOF/TOF mass spectrometer (Bruker Daltonics)ata format Analyzed
xperimental factors Effect of chronic exercise on muscle protein abundance in mdx mice
model for Duchene muscular dystrophy. Modulation by two natural
compounds apocynin and taurinexperimental features Animal model. Male mdx mice divided in:
-sedentary mdx (mdx) mice
-exercised mdx (mdx exe) mice
- mdx exercised mice treated with taurine (mdx exe tau)
-mdx exercised mice treated with apocynin (mdx exe apo)
-C57/BL wild-type mice exercised (wt exe) and control (wt).
Age-matched male wild-type mice (C57BL/10) has been used as referring
phenotype. The training protocol consisted of a 30min running on a
horizontal treadmill (Columbus Instruments, USA) at 12m/min, twice a
week for at least 4 weeks. The doses of taurine and apocynin were 1 g/kg
(orally) and 38mg/kg (1.5 mmol/l in drinking water) respectively.
Proteomics: 2DE and MS were used in order to identify differences in
protein abundance between groups.ata source location Male mdx mice (C57BL/10ScSn-Dmdmdx/J from Jackson Laboratories)
and C57/BL wild-type (wt) mice (from Jackson Laboratories)ata accessibility Data is provided by this articleValue of the data
 These data report for the first time the effect of chronic exercise protocol on protein abundance in
mdx mice.
 These data can provide information about muscle damage induced by an inappropriate exercise in
dystrophic patients.
 These data show the ability of taurine and apocynin to counteract some of exercise-induced pro-
tein alterations.
Table 1
Differentially abundant protein spots that significantly differed between groups, identified by MALDI-TOF/TOF mass spectrometry analysis. The complete list of the proteins, identified by
MALDI-TOF is reported in [1].
Spot
Noa
Protein name ACb Gene Name Cellular component
Go term









Sarcomere organization and muscle contraction
1 LIM domain-binding pro-
tein 3




3 LIM domain-binding pro-
tein 3
Q9JKS4 Ldb3 Z-disc 77.6/.7.9 30.2/9.3 76 8/34 16% [21-32] K.DFNMPLTISR.I
[273-294] R.ILAQMTGTEFMQDPDEE
ALR.R
6 Myozenin-1 Q9JK37 Myoz1 Cytoskeleton 31.4/8.6 31.7/7.9 121 15/77 67% [42-57] R.DVMLEELSLLTNR.G
[69-90] K.FIYENHPDVFSDSSMDHFQK.
F
11 Troponin T, fast skeletal
muscle
Q9QZ47 Tnnt3 Troponin complex 32.2/5.3 31.5/7.8 82 10/43 33% [61-76] K.IPEGEKVDFDDIQK.K
[159-175] K.ALSSMGANYSSYLAK.A
12 Troponin T, fast skeletal
muscle
Q9QZ47 Tnnt3 Troponin complex 32.2/5.3 31.9/9.2 74 8/27 26% [61-76] K.IPEGEKVDFDDIQK.K
[159-175] K.ALSSMGANYSSYLAK.A
13 Myosin regulatory light
chain 2, skeletal muscle
isoform




16 Myosin regulatory light
chain 2, skeletal muscle
isoform
P97457 Mylpf Myosin complex 19/4.8 17.1/4.9 72 6/36 37% [31-42] K.EAFTVIDQNR.D
[41-52] R.DGIIDKEDLR.D
[92-106] K.GADPEDVITGAFK.V
23 Actin, alpha skeletal






Cytoskeleton 42.3/5.2 42.4/5.2 72 14/32 44% [97-116] R.VAPEEHPTLLTEAPLNPK.A
[240-257] K.SYELPDGQVITIGNER.F





























Table 1 (continued )
Spot
Noa
Protein name ACb Gene Name Cellular component
Go term











37 Beta-enolase P21550 Eno3 cytoplasm 47.3/6.7 46.6/6.3 95 8/22 23% [15-29] R.GNPTVEVDLHTAK.G
[239-254] K.VVIGMDVAASEFYR.N
(Respiratory chain complex)
48 NADH dehydrogenase [ubi-
quinone] flavoprotein 2,
mitochondrial
Q9D6J6 Ndufv2 mitochondrion 27.6/7 23.9/5.4 71 8/32 38% [238-247] K.GPGFGVQAGL.
[110-124] R.VYEVATFYTMYNR.K
[41-61] R.DTPENNPDTPFDFTPENYK.R
51 ATP synthase subunit alpha,
mitochondrial
Q03265 Atp5a1 mitochondrion 59.8/9.22 22.5/6.6 72 7/22 17% [334-348] R.EAYPGDVFYLHSR.L
Energy transfert
55 Creatine kinase M-type P07310 Ckm cytoplasm 43.2/6.6 24.3/6.3 61 7/20 21% [116-131] K.GGDDLDPNYVLSSR.V
[156-171] K.LSVEALNSLTGEFK.G
57 Creatine kinase M-type P07310 Ckm Cytoplasm 43.2/6.6 29/6.6 66 10/39 27% [116-131] K.GGDDLDPNYVLSSR.V
[156-171] K.LSVEALNSLTGEFK.G
58 Creatine kinase M-type P07310 Ckm Cytoplasm 43.2/6.6 29.7/6.6 61 7/35 21% [156-171] K.LSVEALNSLTGEFK.G
[210-215] R.DWPDAR.G
[223-237] K.SFLVWVNEEDHLR.V
60 Creatine kinase M-type P07310 Ckm Cytoplasm 43.2/6.6 17.4/7.9 68 9/34 29% [259-267] K.IEEIFKK.A
[269-381] K.GQSIDDMIPAQK.
[341-359] R.LGSSEVEQVQLVVDGVK.L
70 Adenylate kinase iso-
enzyme 1
Q9R0Y5 Ak1 Cytoplasm 21.6/5.7 21.5/5.3 58 5/20 36% [9–22] K.IIFVVGGPGSGK.G
[31-45] K.YGYTHLSTGDLLR.A
71 Adenylate kinase iso-
enzyme 1





selective channel protein 1





a Spot numbers match those reported in the representative 2DE images shown in Fig. 1 and Table 1 in ref. [1]
b Accession number in Swiss-Prot/UniprotKB.
c Based on the calculation using Progenesis SameSpots 4.0 software
d MASCOT MS score (Matrix Science, London, UK; http://www.matrixscience.com). MS matching score greater than 56 was required for a significant MS hit (p-valueo0.05).
e Number of matched peptides correspond to peptide masses matching the top hit from Ms-Fit PMF, searched peptide are also reported.
f Sequence coverage ¼ (number of the identified residues/total number of amino acid residues in the protein sequence) x100%.
















Sequence coverage (in bold) of identified proteins that show an experimental Mr different from expected.
Spot Noa ACb Gene Name cSequence coverage dTheoretical eObserved
Mr (kDa)/ pI Mr (kDa)/ pI e
1 Q9JKS4 Ldb3 1 MSYSVTLTGP GPWGFRLQGG KDFNMPLTIS RITPGSKAAQ SQLSQGDLVV 77.6/.7.9 30.1/9.7
51 AIDGVNTDTM THLEAQNKIK SASYNLSLTL QKSKRPIPIS TTAPPIQSPL
101 PVIPHQKDPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS
151 PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS
201 AETLREMAQM YQMSLRGKAS GAGLLGGSLP VKDLAVDSAS PVYQAVIKTQ
251 SKPEDEADEW ARRSSNLQSR SFRILAQMTG TEYMQDPDEE ALRRSSTPIE
301 HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA
351 ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR
401 PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS
451 PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK
501 STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC
551 NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCERCYEQ
601 FFAPICAKCN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE
651 PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL
701 EGQPFYSKKD KPLCKKHAHA INV
2 Q9JKS4 Ldb3 1 MSYSVTLTGP GPWGFRLQGG KDFNMPLTIS RITPGSKAAQ SQLSQGDLVV 77.6/.7.9 29.6/9.7
51 AIDGVNTDTM THLEAQNKIK SASYNLSLTL QKSKRPIPIS TTAPPIQSPL
101 PVIPHQKDPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS
151 PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS
201 AETLREMAQM YQMSLRGKAS GAGLLGGSLP VKDLAVDSAS PVYQAVIKTQ
251 SKPEDEADEW ARRSSNLQSR SFRILAQMTG TEYMQDPDEE ALRRSSTPIE
301 HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA
351 ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR
401 PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS
451 PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK
501 STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC
551 NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCERCYEQ
601 FFAPICAKCN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE
651 PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL















Table 2 (continued )
Spot Noa ACb Gene Name cSequence coverage dTheoretical eObserved
Mr (kDa)/ pI Mr (kDa)/ pI e
3 Q9JKS4 Ldb3 1 MSYSVTLTGP GPWGFRLQGG KDFNMPLTIS RITPGSKAAQ SQLSQGDLVV 77.6/.7.9 30.2/9.3
51 AIDGVNTDTM THLEAQNKIK SASYNLSLTL QKSKRPIPIS TTAPPIQSPL
101 PVIPHQKDPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS
151 PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS
201 AETLREMAQM YQMSLRGKAS GAGLLGGSLP VKDLAVDSAS PVYQAVIKTQ
251 SKPEDEADEW ARRSSNLQSR SFRILAQMTG TEYMQDPDEE ALRRSSTPIE
301 HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA
351 ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR
401 PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS
451 PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK
501 STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC
551 NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCERCYEQ
601 FFAPICAKCN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE
651 PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL
701 EGQPFYSKKD KPLCKKHAHA INV
51 Q03265 Atp5a1 1 MLSVRVAAAV ARALPRRAGL VSKNALGSSF VGARNLHASN TRLQKTGTAE 59.8/9.22 22.5/6.6
51 MSSILEERIL GADTSVDLEE TGRVLSIGDG IARVHGLRNV QAEEMVEFSS
101 GLKGMSLNLE PDNVGVVVFG NDKLIKEGDV VKRTGAIVDV PVGEELLGRV
151 VDALGNAIDG KGPIGSKTRR RVGLKAPGII PRISVREPMQ TGIKAVDSLV
201 PIGRGQRELI IGDRQTGKTS IAIDTIINQK RFNDGTDEKK KLYCIYVAIG
251 QKRSTVAQLV KRLTDADAMK YTIVVSATAS DAAPLQYLAP YSGCSMGEYF
301 RDNGKHALII YDDLSKQAVA YRQMSLLLRR PPGREAYPGD VFYLHSRLLE
351 RAAKMNDSFG GGSLTALPVI ETQAGDVSAY IPTNVISITD GQIFLETELF
401 YKGIRPAINV GLSVSRVGSA AQTRAMKQVA GTMKLELAQY REVAAFAQFG
451 SDLDAATQQL LSRGVRLTEL LKQGQYSPMA IEEQVAVIYA GVRGYLDKLE
501 PSKITKFENA FLSHVISQHQ SLLGNIRSDG KISEQSDAKL KEIVTNFLAG
551 FEP
55 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 24.3/6.3
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV















56 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 28.8/6.6
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV
351 QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K
57 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 29/6.6
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV
351 QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K
58 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 29.7/6.6
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV
351 QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K
59 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 24.4/6.5
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV















Table 2 (continued )
Spot Noa ACb Gene Name cSequence coverage dTheoretical eObserved
Mr (kDa)/ pI Mr (kDa)/ pI e
60 P07310 Ckm 1 MPFGNTHNKF KLNYKPQEEY PDLSKHNNHM AKVLTPDLYN KLRDKETPSG 43.2/6.6 17.4/7.9
51 FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY
101 KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE
151 RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP
201 LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLRVISM EKGGNMKEVF
251 RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA
301 NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV
351 QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K
90 Q9R1S8 Capn7 1 MDASALERDA VQFARLAVQR DHEGRYSEAV FYYKEAAQAL IYAEMAGSSL 93.3/8.1 17.6/10.3
51 ERIQEKINEY LERVQALHSA VQSKSTDPLK SKHQLDLERA HFLVTQAFDE
101 DEKGNVEDAI ELYTEAVELC LKTSSETADK TLQNKLKQLA RQALDRAEAL
151 SEPLTKPFCK LKSANMKTKT PPVRTHFPLG PNPFVEKPQA FISPQSCDAQ
201 GQKYTAEEIE VLRTTSKING VEYVPFMSVD LRERFAYPMP FCDRLGKLPL
251 SPKQKTTFSK WVRPEDLTNN PTMIYTVSSF SIKQTIVSDC SFVASLAISA
301 AYERRFNKKL ITSIIYPQNK DGEPEYNPCG KYMVKLHLNG VPRKVIIDDQ
351 LPVDHKGELL CSYSNNKSEL WVSLIEKAYM KVMGGYDFPG SNSNIDLHAL
401 TGWIPERIAM HSDSQTFSKD NSFRMLYQRF HKGDVLITAS TGVMTEAEGE
451 KWGLVPTHAY AVLDIREFKG LRFIQLKNPW SHLRWKGRYS ENDVKNWTPE
501 LQKYLNFDPR TAQKIDNGIF WISWDDLCQY YDVVYLSWNP ALFKESTCIH
551 STWDAKQGPV KDAYSLANNP QYKLEVQCPQ GGAAVWVLLS RHITDKDDFA
601 NNREFITMVV YKTDGKKVYY PADPPPYIDG IRINSPHYLT KIKLTTPGTH
651 TFTLVVSQYE KQNTIHYTVR VYSACSFTFS KIPSPYTLSK RINGKWSGQS
701 AGGCGNFQET HKNNPIYQFH IDKTGPLLIE LRGPRQYSVG FEVVAVSIMG
















96 Q80XQ2 Tbc1d5 1 MYKSVSETRH PLQSEEQEVG IDPLFSYSNK TRGDLSQNGR GSNSTLDTEG 92.3/6.3 35.1/6.6
51 TFNSYMKEWE ELFVNNNYLA TVRQKGINGQ LRSSRFRSIC WKLFLCVLPQ
101 DKSQWISKIK ELRAWYSSIK EIHITNPRKA AGQQDLMINN PLSQDEGSLW
151 NKFFQDKELR SMIEQDVKRT FPEMQFFQQE NVRKILTDVL FCYARENEQL
201 LYKQGMHELL APIIFTLHCD HQAFLHASES AQPSEEMKTL LNPEYLEHDA
251 YAMFSQLMET AEPWFSTFEH DGQKGKETLM APIPFARPQD LGPTVAIVTK
301 VNQIQDHLLK KHDIELYMHL NRLEIAPQIY GLRWVRLLFG REFPLQDLLV
351 VWDALFADSL NLSLVDYVFT AMLLYIRDAL ISSNYQTCLG LLMHYPIIGD
401 IHSLILKALF LRDPKRNPRP ATYQFHPNLD YYKARGADLM NKSRTNARGA
451 PLNIHKVSNS LINFGRKLIS PASAPGSMGG PVPGNNSSSS FSAAIPTRTS
501 TEAPRHHLLQ QQQQQQHQQQ QQQQPQQQQQ QHQQQQQQQR LMKSESMPVQ
551 LNKGQSSKTI SSSPSIESLP GGREFTGSPP PSATKKDSFF SNIARSRSHS
601 KTMGRKESEE ELEAQISFLQ GQLNDLDAMC KYCAKVMDMH LVNIQDVVLQ
651 ENLEKEDQIL VSLAGLKQIK DILKGSLRFN QSQLEAGENE QITIADDHYC
701 SSGQDQGSQV PRAAKQASSE MPGCTGGTTP DDFILVSKED EGHRARGAFS
751 GQAQPLLTLR STSGKSRAPA CSPLLFSDPL MGPASASASS SNPSSSPDDD
801 SSKESGFTIV SPLDI
a Spot numbers match those reported in the representative 2DE images shown in Fig. 1 and Table 1 in ref. [1]
b Accession number in Swiss-Prot/UniprotKB.
c Sequence coverage refers to the identified peptides of the protein sequence (bold letters).
d Theoretical molecular mass (Mr) and isoelectric point (pI) according to protein sequence.















Fig. 1. Histograms represent the abundance of each spot (normalized volume, arbitrary units) in all groups studies, namely
mdx, mdx exe, mdx exe apo, mdx exe tau (indicated as mdxþapo and mdxþtau respectively) and wt, evaluated with Pro-
genesis SameSpot software. All spots show a False Discovery Rate (FDR) r0.05. The significant differences between groups
were calculated with GraphPad Prism v6.0 software, using Tukey correction for multiple comparison. Significant differences
between groups are indicated by a line.
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Fig. 1. (continued)
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Fig. 1. (continued)
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Fig. 1. (continued)
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Fig. 1. (continued)
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Fig. 1. (continued)
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Fig. 1. (continued)
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Fig. 2. Picture representing different abundant spots between mdx and mdx exe treated and untreated with compounds.
Detailed data on spot differences were reported in table 4 of ref [1].
T. Gamberi et al. / Data in Brief 18 (2018) 555–575 5711. Data
1.1. MS data
97 differentially abundant spots were identified through the study published in [1]. Among these,
some spots showing low Mascot (PMF) score value or discrepancy between theoretical and calculated
MW or pI, were further analyzed performing peptide sequencing by tandem mass spectrometry. MS/
MS analysis was carried out by using an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker
Daltonics) as described in Materials and Methods, and Table 1 reports detailed MALDI-TOF/TOF data.
12 spots show an experimental Mr different from expected. The sequence coverage of these spots is
reported in Table 2. The muscle protein LIM domain-binding protein 3 (LDB3) was found in three
different spots showing a Mr lower than expected. This protein belongs to Z-disc proteins whose
alteration was correlated with myofibrillar myopathies [2]. Creatin kinase (Ckm) was found in six
spots showing a Mr lower than expected.
1.2. Apocynin and taurine modulate the effect of exercise on mdx mice muscle protein abundance
Fig. 1 reports 97 histograms representing the spot abundance, in each group analysed (mdx, mdx
exe, mdx exe tau, mdx exe apo) evaluated by gel image analysis with ProgenesisSame Spot. Proteins
are divided in categories according to their GO biological process. Protein spot abundance in wt mice
was also evaluated as referring phenotype. Fig. 2 summarizes the modulatory effects of taurine and
apocynin.
1.3. Comparison with wt strain
Table 3 reports differentially abundant protein spots and relative fold changes, between mdx exe
vswt and mdx vswt tibialis anterior muscles. In Fig. 3a diagram represents the relationships between
these three groups. The protocol used for mdx training consisted of a 30min running on a horizontal
treadmill (Columbus Instruments, USA) at 12m/min, twice a week for at least 4 weeks. This protocol
causes significant weakness in the limb strength as measured by a grip strength meter [3]. The in vivo
weakness produced by such a protocol is observed exclusively in mdx mice with no similar effects in
wild type mice [4,5]. In fact, protocols used to induce training effects in wild types mice usually
consist of continuous running at 20m/min for at least 15min using a treadmill slope of 10°, five days
a week, for eight weeks [6]. To exclude training effects in wt animals we checked the amount of
selected proteins in wt animals subjected to the same exercise protocol of mdx mice. In particular, we
Table 3
Differentially abundant protein spots between mdx exe vs wt and mdx vs wt tibialis anterior muscles.
Spot No Protein name afold change
mdx vs wt
afold change
mdx exe vs wt
Sarcomere structure and muscle contraction
3 LIM domain-binding protein 3 ns 1.5
4 LIM domain-binding protein 3 ns 1.7
5 LIM domain-binding protein 3 ns 1.8
6 Myozenin-1 ns 1.4
7 Troponin I, fast skeletal muscle -2.2 ns
8 Troponin I, fast skeletal muscle -1.6 -1.5
9 Troponin I, fast skeletal muscle -1.8 ns
14 Myosin regulatory light chain 2,
skeletal muscle isoform
ns -2.1
15 Myosin regulatory light chain 2,
skeletal muscle isoform
ns -3.7
16 Myosin regulatory light chain 2,
skeletal muscle isoform
-2.1 -4.1
17 Tropomyosin beta chain -2.3 -2.8
18 Tropomyosin alpha-1 chain -1.8 -2.8
20 Myosin light chain 1/3, skeletal
muscle isoform
ns -2.9
23 Actin, alpha skeletal muscle and
Actin, alpha cardiac muscle1
-1.4 ns
24 Actin, alpha cardiac muscle 1 -1.4 -1.6
26 Myotilin ns 1.7
27 Myotilin ns 1.8
Metabolism and energy transfer
30 Fructose-bisphosphate aldolase A ns 1.6
32 Triosephosphate isomerase -1.53 ns
33 Triosephosphate isomerase -1.4 ns
36 Triosephosphate isomerase -1.52 ns
















49 NADH dehydrogenase [ubiqui-
none] 1 beta subcomplex subunit
7
1.8 ns




zyme A transferase 1,
mitochondrial
ns 1.5
55 Creatine kinase M-type -2 ns
56 Creatine kinase M-type ns 1.7
57 Creatine kinase M-type -2.5 ns
59 Creatine kinase M-type 1.8 ns
68 Creatine kinase M-type -1.5 ns
69 Nucleoside diphosphate kinase B ns 3.7
70 Adenylate kinase isoenzyme 1 ns -2.6
Others
72 Alcohol dehydrogenase [NADP(þ)] ns 1.4
T. Gamberi et al. / Data in Brief 18 (2018) 555–575572
Table 3 (continued )
Spot No Protein name afold change
mdx vs wt
afold change
mdx exe vs wt
74 Carbonic anhydrase 3 ns 1.4




81 Serotransferrin 1.5 1.8
82 Serotransferrin ns 1.7
91 26 S protease regulatory subunit 8 ns 1.6
92 Protein disulfide-isomerase A3 ns 1.5
93 Peroxiredoxin-6 -1.6 ns
94 Electron transfer flavoprotein sub-
unit alpha, mitochondrial
ns 1.4
96 TBC1 domain family member 5 ns 1.3
97 Alpha-crystallin B chain ns 1.8
a Fold change was calculated dividing the average of %V of mdx or mdx exe by the average of %V of wt (V
¼volume¼ integration of the optical density over the spot area; %V ¼ V single spot/V total spots included in the reference gel).
Fig. 3. Diagram representing the distribution of differences in spot abundance between groups: 27 protein spots differ
exclusively between mdx exe and wt, 15 protein spots differ exclusively between mdx and wt and 7 spots are different fromwt
in both mdx and mdx exe.
T. Gamberi et al. / Data in Brief 18 (2018) 555–575 573analysed by western blot the amount of several proteins of glycolysis (all increased in mdx exe mice),
oxophos proteins, and PGC-1-alpha and Sirt1 proteins. As shown in Fig. 4 none difference is observed
in the expression level of these proteins.2. Experimental design, materials and methods
The methodologies that allowed the data here presented are described in [1] and in cited refer-
ences. Here, only the protocol for MS/MS data is described.
Trypsin digests of some spots with low Mascot (PMF) score value or with discrepancy between
theoretical and calculated MWor pI were further analyzed performing peptide sequencing by tandem
mass spectrometry. MS/MS analysis was performed by using an Ultraflex III MALDI- TOF/TOF mass
spectrometer (Bruker Daltonics). Two to four PMF peaks showing a high intensity were CID frag-
mented using Argon as collision gas, and MALDI-TOF/TOF tandem MS was performed in LIFT mode by
software controlled data acquisition. Fragmented ions were analyzed using the Flex Analysis software
v.3.0. The MS/MS database searching was carried out in the UniProtKB database using the on-line
available MASCOT MS/MS ion search software. The following parameters were applied for database
Fig. 4. Histograms and representative immunoblot images of glycolytic enzymes: Aldoa, Tpi1 and Eno3 (panel A); PGC1-alpha
and Sirt1 (panel B) and Oxphos complexes from wt and wt exe mice. (n¼5; mean 7 S.D.; t-test unpaired). Normalization of
immunoblot was performed on Coomassie stained gel.
T. Gamberi et al. / Data in Brief 18 (2018) 555–575574searching: taxonomy: Mus musculus, trypsin specificity, one missed cleavage allowed, peptide pre-
cursor mass tolerance: 7100 ppm, fragment mass tolerance: 70.6 Da, peptide precursor charge
state: þ1, carbamidomethylation of cysteine as a fixed modification, oxidation of methionine as a
possible modification. For protein identification, Mascot ion score, peptide coverage by “b” and “y”
ions, and expected value were considered. We considered as significant, peptides with individual ion
scores −10 * Log[P], where P is the probability that the observed match is a random event, that
indicated identity (p o 0.05).Acknowledgements
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